# Supplementary materials: A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

**These are peer-reviewed supplementary materials for the article '****A network meta-analysis of ****immunotherapy-based treatments for ****advanced nonsquamous non-small cell ****lung cancer****' published in the**** ***Journal of Comparative Effectiveness Research***.**

__Additional Methodology__

**Survival analysis****Proportional hazards assumption****Piecewise constant hazard ratios models**

__Figures__

**Fig. S1:**Network of evidence for first-line to progression - progression-free**Fig. S2:**Network of evidence for first-line to progression - overall survival**Fig. S3:**Network of evidence for first-line to progression - progression-free survival and overall survival for the PD-L1 ≥50% subgroup survival

__Tables__

**Table S1a:**Medline search terms used for SLR**Table S1b:**Embase search terms used for SLR**Table S1c:**Cochrane CENTRAL search terms used for SLR**Table S2:**PICOS Statement**Table S3:**Reasons for exclusion of studies from the first-line to progression NMA base case analyses**Table S4:**Reasons for exclusion of studies from the second-line NMA base case analyses

__Data Inputs__

**Table S5:**Input data for first-line to progression PFS – HR**Table S6:**Input data for first-line to progression OS – HR**Table S7:**Input data for second-line PFS – HR**Table S8:**Input data for second-line PFS – median**Table S9:**Input data for second-line OS – HR**Table S10:**Input data for second-line OS – median

__Results__

**Table S11:**Model assessment statistics for the piecewise constant hazard ratio survival models on both OS and PFS**Table S12:**Pairwise hazard ratios for first-line to progression OS (using random effects model)**Table S13:**Pairwise hazard ratios for first-line to progression PFS (using random effects model)**Table S14:**Piecewise analysis: pairwise hazard ratios for first-line to progression - OS (using random effects model)**Table S15:**Piecewise analysis: pairwise hazard ratios for first-line to progression PFS (using random effects model)**Table S16:**Pairwise hazard ratios for first-line to progression OS (using fixed effects model) in the PD-L1 ≥50 subgroup**Table S17:**Pairwise hazard ratios for first-line to progression OS (using random effects model) in the PD-L1 ≥50 subgroup**Table S18:**Pairwise hazard ratios for first-line to progression PFS (using fixed effects model) in the PD-L1 ≥50 subgroup**Table S19:**Pairwise hazard ratios for first-line to progression PFS (using random effects model) in the PD-L1 ≥50 subgroup- Table S20: Pairwise hazard ratios (and credible intervals) for second-line overall survival (using random effects model)
- Table S21: Pairwise hazard ratios (and credible intervals) for second-line progression-free survival (using random effects model)

**References**

**Introduction:** In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. **Materials & methods:** A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. **Results: **Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.